Read more stories about
Montana Biotech >>

MATR Sponsor:

MATR Supporters:

University of Montana research proves that a small dose of medical methamphetamine might go a long way in limiting post-TBI brain damage - Sinapis Pharma raising funds for Trials

May 12, 2014View for printing

A mistake made by a PhD student in a University of Montana lab nearly a decade ago is now on the brink of mid-stage clinical trials as a potential treatment for traumatic brain injuries.

And, most surprising of all, the treatment consists of a small dose of methamphetamine.

It all started when a research assistant in David Poulsen's neuroscience research lab was doing an experiment that involved using high doses of methamphetamine to create brain damage in small animal models. But somewhere along the line, he misread one of the concentrations of meth that he was preparing and accidentally gave a dramatically diluted dose to one group of rats.

With phase 1 safety studies complete, Sinapis is in the middle of raising a $6 million Series B that will fund an upcoming trial in 30 patients with brain injuries, which will establish dosing for the subsequent Phase 2b efficacy study.

Sinapis Pharma

by Deanna Pogorelc

Read more: ... zz31V2yM3Hn
No reader comments so far. Be the first to comment by clicking the button below.

Reprinted under the Fair Use doctrine of international copyright law. Full copyright retained by the original publication. In accordance with Title 17 U.S.C. Section 107, this material is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes.

E-mail this page to a friend!